Cognitive DeclineNCT07198399
Effects of Auri Super Mushroom Daily Gummies on Cognitive Health
A study testing Auri Super Mushroom Daily Gummies in people with Cognitive Decline and Focus Deficit, run by Auri Nutrition at 1 site in United States.
Trial summary
This is a single-arm, open-label, virtual clinical trial evaluating the cognitive health effects of Auri Super Mushroom Daily Gummies in a population of 35 adult participants over 8 weeks. Read more about this study
- Who is it for?
- Ages 30 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cognitive Decline, Focus Deficit
- What is being tested?
- Auri Super Mushroom Daily Gummies
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 35 participants
- Where
- 1 siteUnited States
- Study dates
- 3 Apr 2025to 1 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Be male or female
- Be aged 30+
- Anyone who has been experiencing issues consistently for the last four weeks regarding all of the following:
- Forgetfulness Inability to focus Low energy levels Low mood
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease
- Willing to stop any other products or any medication or supplements that target cognition or cognitive health for the study duration
Show all 12Show fewer
- Willing to maintain their current diet, sleep schedule, and activity level for the duration of the study
- Not undergone any surgeries or invasive treatments in the last six months
- Not had any major illness in the last three months
- Resides in the United States
- Not currently partaking in another research study and will not be partaking in any other research study for the next 8 weeks and at any point during this study's duration
- Willing to consult with their healthcare provider before enrolling in the study if taking any prescription medication
Who cannot join
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
- Anyone with any allergies or sensitivities to any of the study product ingredients
- Anyone taking immunosuppressants
- Anyone taking blood thinners (anticoagulants)
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
- Anyone unwilling to follow the study protocol
- Anyone with a history of substance abuse
- Anyone with intolerance or sensitivity to mushrooms
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Health
This is a single-arm, open-label, virtual clinical trial evaluating the cognitive health effects of Auri Super Mushroom Daily Gummies in a population of 35 adult participants over 8 weeks. Participants will consume two gummies daily and complete validated cognitive testing and self-assessment questionnaires to assess changes in cognitive performance, energy, mood, memory, and overall well-being.
- Conditions
- Cognitive Decline, Focus Deficit
- Being tested
- Auri Super Mushroom Daily Gummies
- Keywords
- Cognitive Health, Functional Mushrooms
- Medical subject headings
- Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Auri Super Mushroom Daily GummiesDietary supplement
Each gummy contains a blend of 12 functional mushroom extracts (300 mg equivalent each).
| Study group | Role | What they receive |
|---|---|---|
| Auri Cognitive Support Supplement | Experimental | Participants will take two Auri Super Mushroom Daily Gummies each morning for 8 weeks with their first meal and a glass of water. Receives: Dietary Supplement: Auri Super Mushroom Daily Gummies |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Cognitive Performance - Digit Span Test
The Digit Span test measures working memory capacity. Participants are presented with a series of numbers and asked to recall them in order.
Performance is scored based on the total number of correctly recalled sequences.
Scale Name: Digit Span Score Range: 0 to 14 Direction: Higher scores indicate better cognitive performance.
Measured: Baseline, Week 2, Week 4, Week 6, and Week 8
Change in Cognitive Performance - Paired Associates Test
The Paired Associates task assesses memory by asking participants to recall which items were previously paired together.
Score is based on the number of correct associations recalled.
Scale Name: Paired Associates Score Range: 0 to 12 Direction: Higher scores indicate better cognitive performance.
Measured: Baseline, Week 2, Week 4, Week 6, Week 8
Change in Attention and Processing Speed - Double Trouble Task
Double Trouble is a Stroop-like task that measures attention control and response inhibition.
Performance is measured by accuracy (%) and completion time (seconds).
Scale Name: Double Trouble Accuracy (%) Range: 0 to 100 Direction: Higher percentage indicates better attention and cognitive control.
Measured: Baseline, Week 2, Week 4, Week 6, Week 8
Secondary outcomes (2)
Self-Reported Focus - Questionnaire Score
Participants rate their ability to focus using a Likert-style scale.
Scale Name: Focus Rating Scale (1-10) Range: 1 (poor focus) to 10 (excellent focus) Direction: Higher scores indicate better focus
Measured: Baseline, Week 2, Week 4, Week 6, and Week 8
Self-Reported Memory - Questionnaire Score
Participants self-assess memory retention using a 10-point Likert scale.
Scale Name: Memory Rating Scale (1-10) Range: 1 (poor memory) to 10 (excellent memory) Direction: Higher scores indicate better memory
Measured: Baseline, Week 2, Week 4, Week 6, and Week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Sep 2025
- Study start3 Apr 2025
- Primary completion1 Aug 2025
- Study completion1 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cognitive DeclineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 35 participants (actual)
Sponsor and investigators
- Lead sponsor
- Auri Nutrition
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07198399
- Sponsor's protocol ID
- 20739
- Status last verified
- Sep 2025
- First submitted
- 14 Sep 2025
- Last updated
- 30 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Health
- ClinicalTrials.gov ID
- NCT07198399
- Acronym / sponsor ID
- 20739
- Conditions
- Cognitive Decline, Focus Deficit
- Keywords
- Cognitive Health, Functional Mushrooms
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 35 participants (actual)
- Lead sponsor
- Auri NutritionIndustry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 3 Apr 2025 (actual)
- Primary completion
- 1 Aug 2025 (actual)
- Study completion
- 1 Aug 2025 (actual)
- First posted
- 30 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-arm, open-label, virtual clinical trial evaluating the cognitive health effects of Auri Super Mushroom Daily Gummies in a population of 35 adult participants over 8 weeks. Participants will consume two gummies daily and complete validated cognitive testing and self-assessment questionnaires to assess changes in cognitive performance, energy, mood, memory, and overall well-being.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Auri Cognitive Support Supplement | Experimental | Dietary Supplement: Auri Super Mushroom Daily GummiesParticipants will take two Auri Super Mushroom Daily Gummies each morning for 8 weeks with their first meal and a glass of water. |
Who may qualify
- Ages
- 30 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Be male or female
- Be aged 30+
- Anyone who has been experiencing issues consistently for the last four weeks regarding all of the following:
- Forgetfulness Inability to focus Low energy levels Low mood
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease
Key exclusion criteria (8 listed)
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
- Anyone with any allergies or sensitivities to any of the study product ingredients
- Anyone taking immunosuppressants
- Anyone taking blood thinners (anticoagulants)
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Auri Super Mushroom Daily GummiesEach gummy contains a blend of 12 functional mushroom extracts (300 mg equivalent each). | Dietary supplement | Auri Cognitive Support Supplement |
Primary outcome
Change in Cognitive Performance - Digit Span Test
Time frame: Baseline, Week 2, Week 4, Week 6, and Week 8
The Digit Span test measures working memory capacity. Participants are presented with a series of numbers and asked to recall them in order. Performance is scored based on the total number of correctly recalled sequences. Scale Name: Digit Span Score Range: 0 to 14 Direction: Higher scores indicate better cognitive performance.
Change in Cognitive Performance - Paired Associates Test
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
The Paired Associates task assesses memory by asking participants to recall which items were previously paired together. Score is based on the number of correct associations recalled. Scale Name: Paired Associates Score Range: 0 to 12 Direction: Higher scores indicate better cognitive performance.
Change in Attention and Processing Speed - Double Trouble Task
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8
Double Trouble is a Stroop-like task that measures attention control and response inhibition. Performance is measured by accuracy (%) and completion time (seconds). Scale Name: Double Trouble Accuracy (%) Range: 0 to 100 Direction: Higher percentage indicates better attention and cognitive control.
2 secondary outcomes
Self-Reported Focus - Questionnaire Score
Time frame: Baseline, Week 2, Week 4, Week 6, and Week 8
Self-Reported Memory - Questionnaire Score
Time frame: Baseline, Week 2, Week 4, Week 6, and Week 8
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Sep 2025.
Related trials for Cognitive Decline
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Recruiting
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Alzheimer Disease, Dementia
RecruitingObservational study
Locus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome)
Ondine Syndrome (Congenital Central Hypoventilation Syndrome)
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingObservational study
Community-based Screening for Alzheimer's Disease
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Auri Super Mushroom Daily Gummies in people with Cognitive Decline and Focus Deficit, run by Auri Nutrition at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Cognitive Performance - Digit Span Test (time frame: Baseline, Week 2, Week 4, Week 6, and Week 8). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2025; AzTrials last refreshed its copy on 8 Nov 2026.